Scientifically reviewed by Prof. h.c. Dr. Farid Saad
In short: There is a bidirectional relationship between chronic inflammation and testosterone levels: inflammatory mediators suppress hormone production, and low testosterone levels, in turn, promote inflammatory processes. Observational studies on psoriasis, Crohn's disease, and type 1 diabetes have shown that testosterone therapy improved not only hormone levels but also disease activity and inflammatory markers. This article examines what conclusions can and cannot be drawn from these findings.
Men with an autoimmune disease who have felt tired, listless, and less capable for years usually attribute this to their underlying condition. This is plausible and often correct. However, there is a second possibility that is rarely investigated in routine care: that their testosterone levels have dropped as a result of chronic inflammation—and that some of their symptoms stem from this.
This connection is well established. What is much less well established—and where this article must be honest about the limitations—is the reverse question: whether testosterone therapy has a beneficial effect on the course of the autoimmune disease itself.
Why inflammation and testosterone are linked
The first part of this connection is well studied. Pro-inflammatory mediators—especially tumor necrosis factor-alpha (TNF-α) and interleukin-6—suppress the hypothalamus-pituitary-gonadal axis, the control system through which the body regulates testosterone production. When chronic inflammation is present, testosterone levels drop. This is not an insignificant side effect, but a sensible adaptation: in an emergency state, the body prioritizes immune defense over reproduction.
The second part is less clear-cut, but mechanistically plausible. Testosterone itself affects the immune system. Androgens inhibit the differentiation of CD4 T cells toward the pro-inflammatory Th1 type and promote the formation of regulatory T cells, which curb excessive immune responses. In animal models, correcting low testosterone levels led to reduced disease severity and lower expression of TNF-α and interleukin-6 (Nasser et al., 2015).
This suggests a hypothesis: if chronic inflammation lowers testosterone levels and low testosterone promotes inflammation, correcting the hormone deficiency could break this cycle at one point. Several observational studies have investigated exactly this.
Psoriasis: PASI scores in a case series
Psoriasis is no longer considered a purely skin disease, but a systemic inflammatory disease with a high rate of comorbidities—especially metabolic syndrome, obesity, and cardiovascular diseases. The inflammatory pathways in psoriasis and atherosclerosis are strikingly similar (Saad, Haider & Gooren, 2016).
In a registry study of 347 hypogonadal men, 15 had a pre-existing diagnosis of psoriasis. They received testosterone undecanoate injections for up to 93 months. The Psoriasis Area and Severity Index (PASI), the most common measure of disease severity, fell on average from 19.33 to 1.88. In every single one of the 15 patients, the PASI fell by at least 75 percent—the threshold considered sufficient treatment success in dermatology. The Physician Global Assessment fell from 4.93 to 0.88. C-reactive protein, an inflammatory marker, also decreased significantly. Most of the improvements occurred during the first 24 months and remained stable thereafter.
One detail is important for context: all 15 patients lost weight. At the start of the study, eight were overweight and seven were obese; by the end, four of the overweight patients had reached a normal weight, and all but one of the obese patients were only overweight. Adipose tissue itself is a source of pro-inflammatory mediators. Some of the skin improvement could therefore be due to weight loss rather than directly to the testosterone.
Crohn's disease: two studies, seven-year follow-up
Two studies on Crohn's disease were conducted by the same research group.
The first was a pilot study of 13 men aged 45 to 67 with a baseline testosterone level averaging 9.0 nmol/l. Their baseline findings were already striking: their CRP was 22.7 mg/dl, compared with 3.5 mg/dl in a control group of 107 hypogonadal men without Crohn's disease. Under testosterone therapy, the Crohn's Disease Activity Index (CDAI) fell from 243 to 89—a score below 150 is considered a period of remission. The CRP fell from 22.7 to 6.9 mg/dl, the white blood cell count decreased, and hemoglobin and hematocrit increased. The improvement occurred during the first 15 months and stabilized thereafter (Haider et al., 2010).
The second, larger study included 92 men from clinics in Germany and Syria who received testosterone undecanoate for up to seven years. Fourteen men chose not to receive the therapy and served as a control group. After 84 months, the CDAI in the testosterone group had fallen from 239.36 to 71.67, high-sensitivity CRP from 12.89 to 1.78 mg/l, and the white blood cell count from 11.93 to 6.21 × 10⁹/l. Liver enzymes AST and ALT also largely normalized. None of these changes were observed in the control group; CRP levels there tended to rise (Nasser et al., 2015).
This control group is the most methodologically interesting part of the study—and at the same time its greatest weakness. Fourteen men is a small number, and they were not randomly assigned; they had chosen not to receive treatment. Those who choose therapy systematically differ from those who refuse it.
Type 1 diabetes: an involuntary experiment
It is well established that men with type 2 diabetes often have low testosterone levels. This was not true for type 1 diabetes for a long time—but newer studies suggest that about 10 percent of men with type 1 diabetes are affected, especially older and overweight men (Saad et al., 2015).
In a registry study of 262 hypogonadal men, nine had type 1 diabetes. They were between 52 and 68 years old, and seven of them were obese. Under testosterone therapy, their weight fell on average from 113.2 to 95.4 kg, their waist circumference from 113.1 to 100.7 cm, and their fasting blood sugar from 9.54 to 5.16 mmol/l. The HbA1c level—long-term blood sugar—was between 8.4 and 9.7 percent at the start and fell during therapy to levels between 5.7 and 6.9 percent.
The most revealing part was unplanned. In seven of the nine men, therapy was interrupted—in one case due to a prostate condition, in six cases due to problems with insurance coverage. During this break, the HbA1c rose again to levels between 7.2 and 9.1 percent, blood sugar increased, and weight and waist circumference rose. After therapy was resumed, all values improved again. No serious cardiovascular events occurred during the entire follow-up period of 80 patient-years.
This involuntary discontinuation and resumption is methodologically stronger than a simple before-and-after comparison because it reveals a temporal relationship in both directions. Nevertheless, with only nine men, it remains a case series.
What these data are worth—and what they are not
A plain-speaking approach is necessary here because the topic is prone to exaggeration.
None of these studies is a randomized, placebo-controlled trial. They are registry studies, pilot studies, and case series with 9 to 92 participants. Without a placebo group, it is impossible to determine how much of the improvement was due to the treatment itself and how much was due to the placebo effect, more intensive medical care, or the natural course of the disease—and Crohn's disease and psoriasis typically occur in flares with spontaneous periods of improvement.
Weight loss is a consistent confounding factor. In all three conditions, the participants lost significant weight. Weight loss itself lowers inflammatory markers and improves metabolic health. In these study designs, it is impossible to clearly separate the effect of testosterone.
There is no information on concomitant medication. In the type 1 diabetes case series, for example, it was not recorded whether the insulin dose had changed. The same applies to immunosuppressive therapy in Crohn's disease and psoriasis.
What remains is a consistent signal across three different diseases that fits a plausible biological mechanism—and is good enough to justify a proper study. It is not good enough to derive a treatment recommendation from it.
What can be practically concluded
Testosterone therapy is not a treatment for autoimmune disease. It does not replace immunosuppressants, biologics, or insulin. Prescribed medication should never be discontinued or reduced on one's own, even though these data seem to suggest it might be appropriate.
The reverse question is more useful: In men with a chronic inflammatory disease who also show symptoms of testosterone deficiency—persistent fatigue, loss of libido, muscle loss, low mood, erectile problems—it is justified to check their hormone status. A deficiency needs to be treated regardless of its cause, and some of the symptoms may stem from this rather than from the underlying condition.
Testing requires care. Testosterone is subject to a daily rhythm; blood should be drawn in the morning between 7 and 11 a.m. A single value is not enough—an unusual result should be confirmed with a second test. When inflammation is active, this is especially important: an acute flare can temporarily lower the value. A low value measured during a flare does not necessarily mean a permanent deficiency. How such a test is conducted is described in our article Testosterone testing: The blood test.
The fundamentals work in both directions. Weight, sleep, and exercise affect both hormone levels and inflammation. This is the area where the evidence is strongest—and it is available regardless of any hormone therapy.
Conclusion
The link between chronic inflammation and low testosterone is real and well established. That correcting a hormone deficiency may also have a beneficial effect on autoimmune disease is a well-founded hypothesis supported by encouraging but methodologically weak data from a single research group.
The sensible approach lies somewhere between ignoring it and overinterpreting it: in the case of a chronic inflammatory disease and appropriate symptoms, it makes sense to check the testosterone level. A proven deficiency should be treated because it requires treatment. And no one should expect testosterone to cure the underlying condition—established therapies are available for that, and they should be administered by the treating specialist.

